TRCT
MRVI icon

Tower Research Capital (TRC)’s Maravai LifeSciences MRVI Stock Holding History

Tower Research Capital (TRC)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.8K Buy
6,282
+1,583
+34% +$5.37K ﹤0.01% 3564
2025
Q4 		$15.3K Sell
4,699
-3,170
-40% -$10.7K ﹤0.01% 3299
2025
Q3 		$22.6K Sell
7,869
-10,152
-56% -$25.9K ﹤0.01% 3204
2025
Q2 		$43.4K Buy
18,021
+9,870
+121% +$20.7K ﹤0.01% 3092
2025
Q1 		$18K Buy
8,151
+4,177
+105% +$16.5K ﹤0.01% 3070
2024
Q4 		$21.7K Sell
3,974
-11,324
-74% -$72.9K ﹤0.01% 3126
2024
Q3 		$127K Buy
15,298
+9,955
+186% +$86.1K ﹤0.01% 2042
2024
Q2 		$38.3K Sell
5,343
-19,318
-78% -$167K ﹤0.01% 3299
2024
Q1 		$214K Buy
24,661
+18,563
+304% +$126K 0.01% 1366
2023
Q4 		$39.9K Sell
6,098
-8,936
-59% -$57.7K ﹤0.01% 3278
2023
Q3 		$150K Buy
15,034
+12,049
+404% +$132K ﹤0.01% 1653
2023
Q2 		$37.1K Sell
2,985
-2,014
-40% -$27.2K ﹤0.01% 2834
2023
Q1 		$70K Buy
4,999
+2,863
+134% +$41.1K ﹤0.01% 2202
2022
Q4 		$30K Buy
2,136
+1,270
+147% +$20K ﹤0.01% 2746
2022
Q3 		$22K Sell
866
-14,487
-94% -$364K ﹤0.01% 3865
2022
Q2 		$436K Buy
15,353
+7,170
+88% +$227K 0.01% 1226
2022
Q1 		$289K Buy
8,183
+7,037
+614% +$236K ﹤0.01% 1489
2021
Q4 		$48K Sell
1,146
-379
-25% -$15.4K ﹤0.01% 2788
2021
Q3 		$75K Sell
1,525
-2,020
-57% -$98.5K ﹤0.01% 2636
2021
Q2 		$148K Buy
3,545
+2,637
+290% +$102K ﹤0.01% 2136
2021
Q1 		$32K Buy
+908
New +$30.1K ﹤0.01% 3523

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s MRVI Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Maravai LifeSciences (MRVI) stake by 34% in Q1 2026, buying an estimated $5.37K and bringing the position to 6,282 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

Tower Research Capital (TRC) first reported a position in MRVI in Q1 2021 and has held it in 21 quarters since. The position peaked at $436K in Q2 2022. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Tower Research Capital (TRC) held 6,282 shares of Maravai LifeSciences worth $17.8K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,583 Maravai LifeSciences shares in Q1 2026, an estimated $5.37K.
  • Maravai LifeSciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3564 holding.
  • Tower Research Capital (TRC) first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Maravai LifeSciences position peaked at $436K in Q2 2022.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.